NEW YORK (GenomeWeb News) – Cellectis and Genoway today announced a sublicensing deal covering Cellectis' homologous recombination technology.

The deal makes animal model firm Genoway the exclusive provider of the technology for research applications in genetically modified rodents. Cellectis retains rights to it for all other applications, such as bioproduction and therapeutics. Cellectis licenses the technology from Institut Pasteur.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.